Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) - Concepedia

Concepedia

Publication | Open Access

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)

DOI Full Paper Access

115

Citations

28

References

2022

Year

Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon, Myung Ah Lee, Hyeon-Su Im, Joung-Soon Jang, Min Hwan Kim, Sejung Park, Beodeul Kang, Moonki Hong,

The Lancet. Gastroenterology & hepatology

Abstract

Boryung Pharmaceutical, Celltrion, National Research Foundation of Korea, National R&D Program for Cancer Control through the National Cancer Center, Yonsei University College of Medicine.

References

	Year	Citations

Page 1